Compositions and methods for inhibiting and interrupting biofilm formation, and for destabilizing established biofilms are provided, the novel compositions including polymeric resins and monomeric non-polymerizable and polymerizable resins. More particularly, the compositions and methods enable the protection and removal of biofilms from surfaces in the context of medical, consumer, domestic, food service, environmental and industrial applications, where the effects constitute beneficial and desirable biofilm attenuating activity.

The invention provides methods for the treatment of vaginal laxity which include delivering a cell-containing composition to the vagina. The composition can include fat tissue to provide a bulking effect to reduce the size of the vaginal opening. The cells can provide healing and revascularization of the vaginal treatment area to sustain the bulking provided by the fat. The invention also provides systems and compositions useful for performing the method, and can include instruments and devices for removal of autologous adipose tissue from a patient (e.g., by liposuction), equipment for the enrichment of cells from adipose tissue, mechanical processing of adipose tissue, and the mixing of cells and processed adipose tissue. Devices for the delivery of the cell compositions to the vagina can also be included in the system.

Vaginal dilator assemblies, devices and kits. Assemblies can include a base, and an adapter. The base can have an inner portion and the adapter can have an outer portion that is complimentary to the inner portion of the base such that the adapter is non-rotatably fitted into the base. Vaginal dilator devices can include a base defining a recess aligned with the longitudinal axis of the base. The recess can have a plurality of step tapered sections. Vaginal dilator kits are also provided that include a plurality of vaginal dilators having different diameters. Each of the plurality of vaginal dilators is configured to be axially aligned and securely fitted into one of the step tapered sections of the recess of the base.

A contraceptive device for intervaginal use includes a relatively thin, saucer-shaped impermeable body having two opposite side faces wherein one of the two side faces is concave in form and the other of the side faces is convex in form. In addition, the impermeable portion includes an amount of copper-including material which is disposed across the side faces of the impermeable portion so that the copper-including material is exposed at locations across the side faces.

A contraceptive device for intervaginal use includes a relatively thin, saucer-shaped impermeable body having two opposite side faces wherein one of the two side faces is concave in form and the other of the side faces is convex in form. In addition, the impermeable portion includes an amount of copper-including material which is disposed across the side faces of the impermeable portion so that the copper-including material is exposed at locations across the side faces.

Various embodiments of an adjustable pessary device are provided. The device can include an elastic ribbon or band, such as Nitinol, encapsulated in a soft or flexible structure, such as a rubber shell. In addition to providing a conforming, comfortable shape, the rubber layer can have additional structures to interface and fit with the anatomical structures within the vagina.

Various embodiments of an adjustable pessary device are provided. The device can include an elastic ribbon or band, such as Nitinol, encapsulated in a soft or flexible structure, such as a rubber shell. In addition to providing a conforming, comfortable shape, the rubber layer can have additional structures to interface and fit with the anatomical structures within the vagina.

Described herein is an intravaginal drug delivery system. In an embodiment the intravaginal drug delivery system includes a progestin and estrogen compound, and releases the active ingredients in a fixed physiological ratio over a prolonged period of time to produce a contraceptive state in a female.

An intrauterine device having at least one first pharmaceutically active ingredient and at least one first layer made of at least a first polymeric material, wherein between about 10 and about 60 v/v % of at least one particulate material is dispersed and/or incorporated in the first polymeric material. The presence of the particulate material will reduce the porosity of the polymer or otherwise obstruct the diffusion of the pharmaceutically active ingredient being released, thereby slowing its rate of release. In this way, it is possible to regulate the release rate and/or initial burst of the device, simply by adjusting the amount of particles/particulate material in the first layer, instead of having to adapt the size of the device to the desired release pattern, which requires expensive changes in production equipment and manufacturing processes.

An intrauterine device having at least one first pharmaceutically active ingredient and at least one first layer made of at least a first polymeric material, wherein between about 10 and about 60 v/v % of at least one particulate material is dispersed and/or incorporated in the first polymeric material. The presence of the particulate material will reduce the porosity of the polymer or otherwise obstruct the diffusion of the pharmaceutically active ingredient being released, thereby slowing its rate of release. In this way, it is possible to regulate the release rate and/or initial burst of the device, simply by adjusting the amount of particles/particulate material in the first layer, instead of having to adapt the size of the device to the desired release pattern, which requires expensive changes in production equipment and manufacturing processes.